Mirror Biologics Announces Publication of Clinical Results Showing Potential for Allo-Priming to Provide Broad Protection to Elderly from Respiratory Viral Infection

Mirror Biologics, Inc. announced today the results of a clinical trial testing the experimental drug AlloStim® in modulating the immune system of elderly individuals to enhance their response to viral infections. The study, published in the journal Vaccines, explored the concept of “Allo-Priming” as a potential universal vaccine against respiratory viruses in the elderly population. Older adults are more susceptible to severe illness from common viruses like the flu, COVID-19, and RSV, leading to increased hospitalizations and healthcare costs. The study’s findings suggest that Allo-Priming could offer broad protection against various respiratory viruses and potential pandemic threats without the need for annual booster shots. Mirror Biologics is now seeking partners to further develop this innovative approach to immune system modulation.